The IPATential150 trial showed that ipatasertib and abiraterone significantly prolonged radiographic progression‐free survival (PFS) in mCRPC with PTEN loss in immunohistochemistry (IHC) staining (HR, 0.65; 95% CI, 0.45–0.95), but failed to benefit those with PTEN intact tumor [6]. Here, PTEN is linked to neoplasm.